Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and$363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range——Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to$425 Million, Reflecting Double-Digit Growth Compared to 2024——NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 1 ...